Seamless Therapeutics, a German biotechnology firm, has successfully concluded a USD12.5 million Seed Financing, a university carve-out including equity financing, in-licensing of an innovative patent portfolio from Technische Universität Dresden and hiring of key personnel. Baker McKenzie provided legal and transactional IP advice to Seamless Therapeutics on the financing and in-licensing aspects of the transaction. […]
Swiss-based travel-tech start-up, Boddy, has entered into a binding merger agreement with TrainAway, a Danish company, to form the largest wellbeing network for travelers worldwide. By affiliating with TrainAway, Boddy will leverage the Danish company’s extensive network of fitness and wellness operators, allowing it to expand its global presence to more than 30 countries […]
Lonza Swiss Finance, a wholly owned subsidiary of the Lonza Group, has successfully placed CHF 300 million 2.1% guaranteed senior bonds due 2029. Credit Suisse, UBS and Zürcher Kantonalbank acted as Joint Lead Managers. Advestra acted as legal counsel to Lonza. The team included partners Annette Weber (pictured left), Thomas Reutter (pictured right) and associate Valérie Bayard (all capital markets) […]
Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases, is to be sold to Genfit. With this acquisition, Genfit intends to expand its product portfolio with a Phase 2 ready programme based on first-in-class scanning liposome technology, a paediatric programme focused on urea cycle disorder […]
Advestra has advised Gnothis on all legal aspects related the two financing rounds of nearly CHF 10 million. Gnothis Holding is a company active in the health sector and has closed this financing rounds this year. Investors include the investment company Nordstjernan and the industrial group Hübner Group. Gnothis, which is based in Cham, is a pioneer in the development […]
Mosanna Therapeutics, a Basel-based biotechnology company, has closed a Seed Financing Round led by Forty51 Ventures. The proceeds will be used for formulation and manufacturing optimization of the molecule MOS118 and for regulatory activities in preparation of the first Phase 1b clinical trial. Mosanna is developing the advanced small molecule MOS118, formerly know as AVE0118, […]
As we announced on February, Promedical, which was acquired earlier this year by a group of investors led by SME Equity Partners and Co-Investor Partners and acting through its parent company, has acquired Lauerz-based Nizell Medical. With this transaction the group further consolidates its position in the Swiss medical consumables market and becomes a leading […]
Swiss biotech company, Engimmune Therapeutics completes its seed financing round raising CHF 15.5 million, co-led by Pureos Bioventures and Novo Holdings with incubation from BaseLaunch. Engimmune Therapeutics is a platform company using cutting-edge technologies to engineer highly potent and specific TCR-based therapies for cancer treatment. Proceeds from the financing will be used to develop novel T-cell […]
Sonova Holding, providers of hearing aid solutions, has completed the placement of CHF 450 million Bonds governed by Swiss law. Application will be made for the Bonds to be listed on the SIX Swiss Exchange. The Bonds will be issued in two tranches, the first tranche with a duration until 2029 and a coupon of […]
KSA Group has taken another important step on the way to the new green building “Dreiklang”, KSA’s new ecological construction project. The KSA Group was able to raise CHF 120 million on the capital market by issuing its first green bond. The offering, which was developed under the leadership of UBS and with the Basellandschaftliche […]
